MedPath

Atrioventricular Node Ablation in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure

Phase 4
Terminated
Conditions
Heart Failure
Interventions
Device: Implantation of CRT device
Device: Implantation of conventional VVI(R) pacemaker
Registration Number
NCT01512381
Lead Sponsor
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Brief Summary

The purpose of this study is to determine whether cardiac resynchronization therapy (CRT) is superior to interventricular right ventricle (RV) septal pacing in respect of reverse remodeling (LV ESD) and morbidity in patients with less preserved (less than 45%) ejection fraction (EF), persistent/permanent atrial fibrillation (AF) who successfully received atrioventricular (AV) junction ablation ablation (100% pacemaker dependency)

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Age of 18-75 years
  • CHF II-III NYHA
  • Persistent/permanent AF requiring AV node ablation
  • LVEF < 45%
  • Signed informed consent
  • Able to complete all testing required by the clinical protocol
Exclusion Criteria
  • Myocardial infarction or stroke less than 3 months prior to randomization
  • Patients who require revascularization, radiofrequency ablation of pulmonary veins and substrate of AF
  • The congenital and acquired heart diseases, LV aneurysm, which requires a surgical correction
  • Active inflammatory and autoimmune diseases of a myocardium
  • The thyrotoxicosis
  • The diseases that limit life expectancy (cancer, tuberculosis, etc.)
  • Contraindications to anticoagulants administration at CHADS2> 2
  • Uncompliant patients

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CRTImplantation of CRT device-
pacemakerImplantation of conventional VVI(R) pacemaker-
Primary Outcome Measures
NameTimeMethod
Left Ventricle End-Systolic Volume (LV ESV)12 months
Secondary Outcome Measures
NameTimeMethod
Echocardiographic indexes of LV remodeling12 months
Changes in NYHA functional class measured by peak V O2 oxygen consumption and distance of 6-minute walk test12 months
Changes in Quality of Life (measured by Minnesota Living with Heart Failure Questionnaire)12 months
Rate of cardiovascular events (hospitalization for worsening heart failure)12 month

Trial Locations

Locations (1)

Almazov Federal Heart, Blood and Endocrinology Centre

🇷🇺

Saint-Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath